Antibodies to watch in 2010

New challenges to medicare beneficiary access to mAbs

(2010) Joshua Cohen et al.   mAbs

Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates

(2009) L. E. Weisman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

(2009) Akihiro Takeshita et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

(2009) Kevan C. Herold et al.   CLINICAL IMMUNOLOGY

Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy

(2009) J. Veeken et al.   CURRENT CANCER DRUG TARGETS

Anti-CD3 mAbs for treatment of type 1 diabetes

(2009) Adam Kaufman et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations

(2009) F. Roufosse   HAEMATOLOGICA

Insulin-like growth factor receptor type I as a target for cancer therapy

(2009) Liliane Goetsch et al.   Immunotherapy

Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults

(2009) Leonard E. Weisman et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

(2009) Michael P. Cancro et al.   JOURNAL OF CLINICAL INVESTIGATION

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer

(2009) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis

(2009) C. Scholz et al.   Journal of Crohns & Colitis

Tanezumab, an Anti-Nerve Growth Factor (NGF) antibody, for the treatment of chronic low back pain (CLBP) – a randomized, controlled, double-blind, phase 2 trial

(2009) N. Katz et al.   JOURNAL OF PAIN

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

(2008) C. C. Portera et al.   CLINICAL CANCER RESEARCH

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology

Monoclonal Antibodies as Innovative Therapeutics

(2008) Janice Reichert   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

41 POSTER DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B

(2008) N.J. Serkova et al.   EJC SUPPLEMENTS

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost

(2008) David A. Reardon et al.   NEURO-ONCOLOGY

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

(2008) Marc E. Rothenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

(2008) J. J. Lammerts van Bueren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA